COVID-19 cases have been reported as a global threat and several studies are being conducted using various modelling techniques to evaluate patterns of disease dispersion in the upcoming weeks. Here we propose a simple statistical model that could be used to predict the epidemiological extent of community spread of COVID-19from the explicit data based on optimal ARIMA model estimators.
 
  Raw data was retrieved on confirmed cases of COVID-19 from Johns Hopkins University (https//github.com/CSSEGISandData/COVID-19) and Auto-Regressive Integrated Moving Average (ARIMA) model was fitted based on cumulative daily figures of confirmed cases aggregated globally for ten major countries to predict their incidence trend. Statistical analysis was completed by using R 3.5.3 software.
 
  The optimal ARIMA model having the lowest Akaike information criterion (AIC) value for US (0,2,0); Spain (1,2,0); France (0,2,1); Germany (3,2,2); Iran (1,2,1); China (0,2,1); Russia (3,2,1); India (2,2,2); Australia (1,2,0) and South Africa (0,2,2) imparted the nowcasting of trends for the upcoming weeks. These parameters are (p, d, q) where p refers to number of autoregressive terms, d refers to number of times the series has to be differenced before it becomes stationary, and q refers to number of moving average terms. Results obtained from ARIMA model showed significant decrease cases in Australia; stable case for China and rising cases has been observed in other countries.
 
  This study tried their best at predicting the possible proliferate of COVID-19, although spreading significantly depends upon the various control and measurement policy taken by each country.
 This study tried their best at predicting the possible proliferate of COVID-19, although spreading significantly depends upon the various control and measurement policy taken by each country.A two-year-old boy went to the doctor for hypokalemia and metabolic alkalosis. Laboratory examination revealed that urinary potassium excretion and serum aldosterone level increased, at the same time with hyperthyroidism and thyroid related antibodies positive.Genetic testing showed that there was a complex heterozygous mutation in SLC12A3 gene ,c.1077C>G(p.N359K) and c.1567G>A(p.A523?)，the final diagnosis was Gitelman syndrome and autoimmune hyperthyroidism.Gitelman syndrome is an autosomal recessive genetic disease caused by the inactivation mutation of SLC12A3 gene. The onset age is more than 6 years old, mainly manifested as low blood potassium, low blood sodium, low blood chlorine, metabolic alkalosis, increased urine potassium and urine chlorine excretion and low urine calcium.Autoimmune hyperthyroidism due to the autoimmune disorders. The highest incidence rate in children is Graves' disease, followed by chronic lymphocytic thyroiditis.Several cases of Gitelman syndrome with autoimmune hyperthyroidism had been identified, most of which were Asian adults, and the case we identified is the first reported case of children under 14 years old with both Gitelman syndrome and autoimmune hyperthyroidism.At the same time, we carried out high-precision clinical exosome analysis of the gene of this case, and further explored the relationship between Gitelman syndrome and autoimmune hyperthyroidism from the perspective of gene.
  The stamen is a byproduct of saffron (Crocus sativus) flowers. Herein, its cardiovascular effects were evaluated on hypertension induced by angiotensin II (AngII) and NG-nitro-L-arginine methyl ester (L-NAME), as well as baroreflex sensitivity (BRS).
 
  Rats were randomly divided into 10 groups 1) control, 2) AngII (50 ng/kg, i.v.), 3) losartan (10 mg/kg, i.p.) + AngII, 4) L-NAME (10 mg/kg, i.v.), 5) sodium nitroprusside (SNP) (50 mg/kg, i.p.) + L-NAME, 6, 7) saffron stamen extract (SS) (100 and 200 mg/kg, i.p.) + AngII and 8, 9) SS (100 and 200 mg/kg) + L-NAME, and 10) SS (200 mg/kg) + phenylephrine (Phen, i.v.). The treated rats first received two doses of SS, 30 min after the injection of L-NAME, AngII, and Phen in separate groups. The cardiovascular parameters were recorded by the PowerLab apparatus via an angiocatheter inserted into the femoral artery. The maximal changes (∆) of mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR) in the treated groups were compared with thosfect on AngII, increasing nitric oxide production, or improving baroreflex sensitivity.
  Diabetic retinopathy is amongst the most common microvascular complication associated with diabetes. Controlling blood glucose level alone cannot manage diabetes associated complications.  https://www.selleckchem.com/  Thus, mechanism that additionally prevent diabetes associated complication are need of the hour, driving the researchers towards herbal therapies. Terminalia catappa is renowned for its anti-inflammatory, antioxidant, anti-hyperglycemic and anti-angiogenic activity. The current study explores the effect of Terminalia catappa fruit extract in streptozotocin-induced diabetic retinopathy in rats.
 
  Streptozotocin-induced chronic diabetic rat model was utilized in the study. Hydro-alcoholic fruit extract of T. catappa in 20mg/kg, 30mg/kg and 40mg/kg dose and standard anti-diabetic drug, glibenclamide (10mg/kg) was given orally. Retinopathy was evaluated by monitoring lenticular, fundus images and measuring arteriole and venule tortuosity index. Oxidative, angiogenic and inflammatory biomarkers were assessed at 12th week in reti-angiogenic and anti-inflammatory actions, and thus has a potential to be used in diabetes-induced retinopathy.
  Coronavirus disease 2019 (COVID-19) is a newly discovered multi-organ disease caused by the novel coronavirus SARS-CoV-2. Currently, there are no official guidelines on the pharmacological treatment of COVID-19. Lopinavir/ritonavir is a licensed antiviral treatment against HIV and has shown activity against other coronaviruses.
 
  In this study, we review the evidence of the use of lopinavir/ritonavir as a potential treatment candidate against COVID-19.
 
  This systematic review has been registered in PROSPERO (CRD42020182067). A systematic search of the literature for the observational and randomized controlled trial was conducted in PubMed, PubMed Central, and Google Scholar through May 2nd, 2020. Two reviewers independently searched and selected. The risk of bias was evaluated using the Jadad scale, Newcastle-Ottawa Quality assessment tool, and National Institute of Health quality assessment tool.
 
  A total of 1,965 articles were screened from which 6 articles were selected. Of 6 articles that were included in this study, 4 reported no significant benefit in clinical improvement with lopinavir/ritonavir when compared to standard care of treatment, while 2 studies reported otherwise.